沙利度胺联合化疗治疗晚期大肠癌的疗效观察

The Observation of Efficacy of Thalidomide Combined with Chemotherapy in the Treatment of Advanced Colorectal Cancer

目的评价沙利度胺联合化疗治疗晚期大肠癌的临床疗效及安全性。方法 52例入组患者随机分为治疗组和对照组,治疗组采用沙利度胺联合mFOLFOX方案;对照组采用mFOLFOX方案。4个周期后分别评定疗效和安全性。结果治疗组和对照组的有效率分别为30.8%和23.1%,差异无统计学意义(P>0.05)。两组主要毒副反应均为骨髓抑制、乏力、嗜睡等,毒副反应总发生率差异无统计学意义(P>0.05)。两组患者治疗前后体能评分变化差异无统计学意义(P>0.05)。结论沙利度胺联合mFOL-FOX方案治疗晚期大肠癌的疗效好,毒副反应轻。

Objective To evaluate the efficacy and safety of thalidomide combined with chemotherapy in the treatment of patients with advanced colorectal cancer. Methods Fifty two patients with advanced coloreetal cancer were divided randomly into two groups, the trial group and the control group. The trial group was treated with thalidomide plus mFOLFOX regimen chemotherapy. The control group received mFOLFOX regimen. After the treatment, the efficacyand safety were observed. Results The overall response rate was 30.8% in the trial group and 23.1% in the control group （ P 〉 0.05 ）. The main toxicities were marrow depression, anergy and lethargy in the two groups. There were no significant differences in toxicifies and performance status between the two groups （ P 〉 0. 05 ）. Conclusion Thalidomide combined with mFOLFOX regimen has showed good effect on advanced colorectal cancer without increased toxicities.